Time-dependent endpoints as predictors of overall survival in multiple myeloma

被引:19
作者
Felix, Jorge [1 ]
Aragao, Filipa [1 ]
Almeida, Joao M. [1 ]
Calado, Frederico J. M. [1 ]
Ferreira, Diana [1 ]
Parreira, Antonio B. S. [2 ]
Rodrigues, Ricardo [3 ]
Rijo, Joao F. R. [4 ]
机构
[1] Exigo Consultores, P-2860021 Alhos Vedros, Portugal
[2] Portuguese Oncol Inst Lisboa, Lisbon, Portugal
[3] Univ Lisbon, Fac Pharm, P-1699 Lisbon, Portugal
[4] Hosp Egas Moniz, Lisbon, Portugal
关键词
Multiple myeloma; Overall survival; Survival predictors; Time-dependent endpoint; Time to progression; PROGRESSION-FREE-SURVIVAL; PREDNISONE PLUS THALIDOMIDE; METASTATIC COLORECTAL-CANCER; HEALTH TECHNOLOGY-ASSESSMENT; RANDOMIZED CONTROLLED-TRIALS; STEM-CELL TRANSPLANTATION; LARGE-SAMPLE PROPERTIES; PHASE-III TRIALS; ELDERLY-PATIENTS; CLINICAL-TRIALS;
D O I
10.1186/1471-2407-13-122
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Supporting health care sector decisions using time-dependent endpoints (TDEs) such as time to progression (TTP), progression-free survival (PFS), and event-free survival (EFS) remains controversial. This study estimated the quantitative relationship between median TDE and median overall survival (OS) in multiple myeloma (MM) patients. Methods: Studies (excluding allogeneic transplantation) published from 1970 to 2011 were systematically searched (PubMed). The nonparametric Spearman's rank correlation coefficient measured the association between median TDE and OS. The quantitative relationship between TDEs and OS was estimated with a two-step approach to a simultaneous Tobit model. Results: We identified 153 studies: 230 treatment arms, 22,696 patients and mean study duration of 3.8 years. Mean of median TDEs was 22.5 months and median OS was 39.1 months. Correlation coefficients of median TTP, PFS, and EFS with median OS were 0.51 (P = 0.003), 0.75 (P < 0.0001), and 0.84 (P < 0.0001), respectively. We estimate a 2.5 month (95% confidence interval, 1.7-3.2) increase in median OS for each additional month reported for median TDEs. There was no evidence that this relationship differed by type of surrogate. Conclusion: TDEs predict OS in MM patients; this relationship may be valuable in clinical trial design, drug comparisons, and economic evaluation.
引用
收藏
页数:12
相关论文
共 92 条
  • [41] End points and United States food and drug administration approval of oncology drugs
    Johnson, JR
    Williams, G
    Pazdur, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (07) : 1404 - 1411
  • [42] Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis
    Johnson, Kent R.
    Ringland, Clare
    Stokes, Barrie J.
    Anthony, Danielle M.
    Freemantle, Nick
    Irs, Alar
    Hill, Suzanne R.
    Ward, Robyn L.
    [J]. LANCET ONCOLOGY, 2006, 7 (09) : 741 - 746
  • [43] Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies
    Korn, Edward L.
    Freidlin, Boris
    Abrams, Jeffrey S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) : 2439 - 2442
  • [44] Improved survival in multiple myeloma and the impact of novel therapies
    Kumar, Shaji K.
    Rajkumar, S. Vincent
    Dispenzieri, Angela
    Lacy, Martha Q.
    Hayman, Suzanne R.
    Buadi, Francis K.
    Zeldenrust, Steven R.
    Dingli, David
    Russell, Stephen J.
    Lust, John A.
    Greipp, Philip R.
    Kyle, Robert A.
    Gertz, Morie A.
    [J]. BLOOD, 2008, 111 (05) : 2516 - 2520
  • [45] Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points
    Lee, L.
    Wang, L.
    Crump, M.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (06) : 1392 - 1403
  • [46] Little R. J. A., 2002, STAT ANAL MISSING DA, V2nd
  • [47] A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
    Lokhorst, Henk M.
    van der Holt, Bronno
    Zweegman, Sonja
    Vellenga, Edo
    Croockewit, Sandra
    van Oers, Marinus H.
    Borne, Peter von dem
    Wijermans, Pierre
    Schaafsma, Ron
    de Weerdt, Okke
    Wittebol, Shulamiet
    Delforge, Michel
    Berenschot, Henriette
    Bos, Gerard M.
    Jie, Kon-Siong G.
    Sinnige, Harm
    van Marwijk-Kooy, Marinus
    Joosten, Peter
    Minnema, Monique C.
    van Ammerlaan, Rianne
    Sonneveld, Pieter
    [J]. BLOOD, 2010, 115 (06) : 1113 - 1120
  • [48] Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
    Ludwig, Heinz
    Beksac, Meral
    Blade, Joan
    Boccadoro, Mario
    Cavenagh, Jamie
    Cavo, Michele
    Dimopoulos, Meletios
    Drach, Johannes
    Einsele, Hermann
    Facon, Thierry
    Goldschmidt, Hartmut
    Harousseau, Jean-Luc
    Hess, Urs
    Ketterer, Nicolas
    Kropff, Martin
    Mendeleeva, Larisa
    Morgan, Gareth
    Palumbo, Antonio
    Plesner, Torben
    San Miguel, Jesus
    Shpilberg, Ofer
    Sondergeld, Pia
    Sonneveld, Pieter
    Zweegman, Sonja
    [J]. ONCOLOGIST, 2010, 15 (01) : 6 - 25
  • [49] Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
    Ludwig, Heinz
    Hajek, Roman
    Tothova, Elena
    Drach, Johannes
    Adam, Zdenek
    Labar, Boris
    Egyed, Miklos
    Spicka, Ivan
    Gisslinger, Heinz
    Greil, Richard
    Kuhn, Ingrid
    Zojer, Niklas
    Hinke, Axel
    [J]. BLOOD, 2009, 113 (15) : 3435 - 3442
  • [50] Maroun JA, 2011, CURR ONCOL, V18, pS3